QUANTA-CLOUD-TECHNOLOGY
Quanta Cloud Technology (QCT), a global data center solution provider, will showcase its cutting-edge High-performance Computing (HPC) and AI solutions with vertical applications at the ISC High Performance Conference 2022 , from May 29 to June 2 in Hamburg, Germany at Booth D412 . These unique solutions combine QCT’s advanced hardware infrastructures with software technologies to help build scalable, converged HPC and AI environments across many industries while shortening the time to implement projects so researchers can fully concentrate on their research.
QCT will showcase the following solutions and servers that drive faster time-to-value:
- QCT Platform on Demand (QPOD): QPOD is a workload-driven and purpose-built solution for academia, research institutes, or medical centers, fully integrated with hardware infrastructures, cluster deployment, monitoring and management tools to fulfill HPC and AI workloads. On top of the infrastructure, QCT has also worked with application ISVs to ensure the solution is pre-configured and pre-validated for HPC applications.
- High Performance Storage: Enabled by Intel® Optane™ persistent memory, Distributed Asynchronous Object Storage (DAOS) offers dramatic improvements to storage I/O to accelerate HPC, AI, analytics, and cloud projects. QCT’s advanced storage servers equipped with the DAOS open-source software-defined object store have also brought world-class IOPS and bandwidth as they have ranked on the IO500 and 10-Node Challenge during SC21.
- QuantaGrid D53X-1U: a 1U compute node server optimized by 3rd Gen Intel® Xeon® Scalable processors with built-in AI Accelerators and Intel® Optane™ persistent memory 200 series to propel DAOS and enable AI, HPC and virtualization workloads.
- QuantaGrid D53XQ-2U: a 2U server that benefits from DAOS fueled by Intel® Optane™ persistent memory on the Intel Xeon Scalable platform and equipped with acceleration card expansion slots to power AI, analytics, bioscience, HPC, and even cloud computing workloads.
For more information on QCT’s high-performance storage product line, join QCT’s speaking session titled “Innovative High-performance Storage for AI/HPC in the Exascale Era” at the HPC Solutions Forum (Hall H, Booth J901) on May 31 at 2:00 pm. Our Technical Manager and Solution Architect, Grover Hwang, will give a deep dive on using DAOS to achieve less I/O wait and lower latency when running real-world AI/HPC applications.
“QCT is excited to bring our latest HPC solutions built for compute and graphic-intensive workloads to ISC 2022,” said QCT President Mike Yang. “As an infrastructure builder, QCT leverages our robust R&D capabilities and strong software ecosystem support to tune our solutions all the way from hardware to the software stack, accelerating digital transformation in fields across weather forecasting, NGS, molecular dynamics and more.”
Visit QCT Booth D412 at ISC22 and http://www.qct.io to learn more.
About QCT
QCT is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. http://www.qct.io
Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005020/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom